Sheena Jonathan, who serves as both a co-founder and a director at Natera, Inc. (NASDAQ: NTRA), recently completed a series of stock sales totaling $329,809. The transactions took place on June 17, 2026, involving the disposal of 1,500 shares of the company’s common stock. These shares were executed at weighted average prices that ranged from $218.1371 to $222.144 per share.
The shares disposed of were held indirectly by Ms. Jonathan for the benefit of the beneficiaries of the Caraluna 1 Trust and Caraluna 2 Trust. Ms. Jonathan has disclaimed beneficial ownership over these securities. All sales were pre-arranged under a Rule 10b5-1 trading plan that was established on June 7, 2024. Following these transactions, Ms. Jonathan directly holds 249,352 shares of Natera common stock.
The insider sale activity comes at a time when Natera’s stock has delivered a 34% return over the past year. The company currently trades above its fair value estimate, suggesting the stock may be overvalued at current levels. Natera maintains a market capitalization of $32.6 billion.
In other recent developments, Natera held its annual meeting where shareholders approved an amendment to the company’s 2015 Equity Incentive Plan. The amendment increased the shares reserved for issuance by 3.2 million. Additionally, Natera announced the appointment of Thomas Lynch and Eric Rubin, both oncology experts, to its board of directors.
On the analyst front, RBC Capital initiated coverage on Natera with an Outperform rating, citing growth opportunities in minimal residual disease monitoring. Wolfe Research also initiated coverage with an Outperform rating, setting a price target of $260 based on a long-term discounted cash flow model. Meanwhile, Goldman Sachs initiated coverage with a Neutral rating and a price target of $245, noting Natera’s leadership in the minimal residual disease market and strong commercial execution.